Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.48 USD | -5.43% | -7.64% | +107.53% |
05-07 | HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating | MT |
05-06 | Rate Cut Hopes Lift Exchange-Traded Funds, Equity Futures Pre-Bell Monday | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+107.53% | 354M | |
+9.86% | 118B | |
+10.11% | 106B | |
-11.46% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.61% | 15.97B | |
+6.47% | 14.03B | |
+16.70% | 11.67B |
- Stock Market
- Equities
- ADCT Stock
- News ADC Therapeutics SA
- ADC Therapeutics' Joint Venture Doses First Patient in Phase 3 Trial of Lymphoma Drug Candidate Zynlonta